Morphotek Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 104
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $325M
Latest Deal Amount

Morphotek General Information

Description

Developer of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The company conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Primary Office
  • 210 Welsh Pool Road
  • Exton, PA 19341
  • United States
+1 (610) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Morphotek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 17-Apr-2007 $325M 0000 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series D) 13-Oct-2006 0000 0000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 19-Feb-2004 0000 0000 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 15-Aug-2001 0000 0000 000.00 Completed Product Development
2. Early Stage VC (Series A) 01-May-2001 $2M $2M 000.00 Completed Product Development
1. Accelerator/Incubator Completed Product Development
To view Morphotek’s complete valuation and funding history, request access »

Morphotek Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 000,000,000 00.000000 00 00.00 00.00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00.00 00.000
Series B 9,219,592 $0.001000 8% $1.07 $1.07 $0.58 9.01%
Series A 2,040,830 $0.001000 8% $0.98 $0.98 $0.57 1.88%
To view Morphotek’s complete cap table history, request access »

Morphotek Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The c
Drug Discovery
Exton, PA
104 As of 2010
0000
0000 0000-00-00
000000&0 0000

00000000

t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse ci
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000 00

a commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Morphotek Competitors (102)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 000000 - 000 00000
You’re viewing 5 of 102 competitors. Get the full list »

Morphotek Patents

Morphotek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3026991-A1 Lysine conjugated immunoglobulins Pending 10-Jun-2016 000000000
AU-2017279352-A1 Lysine conjugated immunoglobulins Pending 10-Jun-2016 000000000
EP-3468614-A1 Lysine conjugated immunoglobulins Pending 10-Jun-2016 000000000
US-20210171998-A1 Lysine conjugated immunoglobulins Pending 10-Jun-2016 000000000
JP-2019525897-A Lysine-conjugated immunoglobulin Pending 10-Jun-2016 C12P21/02

Morphotek Executive Team (4)

Name Title Board Seat Contact Info
Rodney Dausch Chief Financial Officer & Vice President of Operations
Luigi Grasso Ph.D Senior Vice President, Research & Development, Co-Founder & Chief Scientific Officer
Nicholas Nicolaides Ph.D Co-Founder, Chief Executive Officer & President
You’re viewing 3 of 4 executive team members. Get the full list »

Morphotek Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morphotek Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Applied Genomic Technology Capital Fund Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Burrill & Co Merchant Banking Firm Minority 000 0000 000000 0
CB Health Ventures Venture Capital Minority 000 0000 000000 0
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Morphotek Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000000 05-Apr-2011 0000000000 Biotechnology
0000000000000 05-Apr-2011 0000000000 Pharmaceuticals
Transmolecular 01-Mar-2011 Merger/Acquisition Biotechnology
To view Morphotek’s complete acquisitions history, request access »